News >

Therapeutic Developments in AML Lead to Sequencing Questions

Ellie Leick
Published: Wednesday, Jul 03, 2019

Robert L. Redner, MD

Robert L. Redner, MD

The FDA approval of 8 new agents in the acute myeloid leukemia (AML) paradigm in the past 3 years has offered more options for targeted treatment, leading to further trials on combination and sequencing strategies, explained Robert L. Redner, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication